XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF CASH FLOWS
¥ in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
CNY (¥)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
CNY (¥)
Dec. 31, 2020
CNY (¥)
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss ¥ (768,990) $ (111,492) ¥ (522,672) ¥ (404,029)
Adjustments to reconcile net loss to net cash generated from operating activities:        
Share-based compensation (note 23) (5,919) (858) 14,680 20,621
Depreciation of property, plant and equipment (note 9) 88,692 12,859 64,288 55,030
Amortization of intangible assets (note 12) 34,495 5,001 30,171 15,756
Amortization of land lease payments (note 10) 9,627 1,396 9,621 9,513
Lease expense to reduce operating lease ROU 19,322 2,801 21,720 23,030
(Income) loss from equity method investments (17,647) (2,559) (18,163) (6,021)
Change in fair value of derivative liability (note 21) (1,015) (147) 39 0
(Gain) loss on disposal of long-lived assets 3   0 (677)
Deferred tax expense (benefit) (71,848) (10,417) 11,257 (13,347)
Allowance for doubtful accounts, net 5,400 783 2,555 6,058
Impairment of long-lived assets 0   0 8,500
Interest and consultation expenses 120,357 17,450 73,789 81,359
Loss on disposal of subsidiary (note 4) 61,546 8,923 0 14,894
Gain from disposal of an equity method investment (note 14)     0 (7,837)
Loss from agreements termination with a cooperative hospital 204,250 29,613 0 0
Changes in operating assets and liabilities net of effects of acquisition and disposals:        
Accounts receivable 644 93 (64,450) (6,167)
Prepayments and other current assets (130,156) (18,871) (30,908) (82,497)
Inventories (46,750) (6,778) (4,352) (14,446)
Other non-current assets (15) (2) (175) 392
Accounts payable 113,743 16,491 262,842 11,119
Accrued expenses and other liabilities 119,055 17,261 (2,515) 15,171
Deferred revenue 57,168 8,289 (193,464) 84,543
Income tax payable 818 119 (858) 105
Accrued unrecognized tax benefit (6,539) (948) 621 (28,012)
Operating lease liabilities (2,935) (426) (13,339) (12,824)
Net cash used in operating activities (216,694) (31,419) (359,313) (229,766)
CASH FLOWS FROM INVESTING ACTIVITIES        
Purchase of land use right (215) (31) 0 (7,170)
Investment in equity method investees (2,300) (333) (61,159) (163,844)
Prepayments for long-term investments     0 (28,490)
Investment in equity investments without readily determinable fair value     (6,439) 0
Acquisitions of business, net of cash acquired     1,569 (8,336)
Acquisitions of property, plant and equipment (222,980) (32,329) (278,977) (168,023)
Acquisitions of intangible assets (818) (119) (19,712) (1,028)
Deposits for the purchases of property, plant and equipment (160,793) (23,313) (481,604) (336,681)
Proceeds from disposal of equity method investment     0 33,020
Proceeds from disposal of property, plant and equipment 5,635 817 212,975 271
Proceed from agreements termination with a cooperative hospital 238,093 34,520 0 0
Proceeds from principal portion of direct financing leases 7,536 1,093 31,525 24,842
Proceeds from disposal of a subsidiary     0 201,554
Cash distribution from equity method investments 5,101 740 15,863 0
Purchase of available-for-sale debt securities     0 (80,000)
Redemption of available-for-sale debt securities 11,949 1,732 19,978 0
Net cash used in investing activities (118,792) (17,223) (565,981) (533,885)
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from short-term bank borrowings 217,470 31,530 126,112 740,434
Proceeds from long-term bank and other borrowings 422,765 61,295 386,635 857,110
Proceeds from convertible note (note 22)     20,000 0
Borrowings from related parties (note 25) 220,369 31,951 24,432 26,560
Repayment to related parties (note 25) (82,915) (12,022) (80,886) 0
Repayment of short-term bank and other borrowings (197,598) (28,649) (24,706) (1,029,176)
Repayment of long-term bank and other borrowings (197,003) (28,563) (206,057) (241,825)
Purchase of subsidiary shares from noncontrolling interests     (4,581) (25,653)
Capital injection from a noncontrolling interests in a subsidiary   0 1,500 110,852
Proceeds from issuance of contingently redeemable noncontrolling interests of a subsidiary     400,000 700,000
Net cash generated from financing activities 383,088 55,542 642,449 1,138,302
Effect of foreign exchange rate changes on cash and cash equivalent and restricted cash (47,170) (6,837) (4,639) (2,563)
Net increase (decrease) in cash 432 63 (287,484) 372,088
Cash and cash equivalents and restricted cash at beginning of the year 158,911 23,040 446,395 74,307
Cash and cash equivalents and restricted cash at end of the year 159,343 23,103 158,911 446,395
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets        
Cash and cash equivalents 158,283 22,949 157,386 334,264
Restricted cash, current portion 1,060 154 1,387 4,661
Restricted cash, noncurrent portion     138 107,470
Total cash and cash equivalents and restricted cash 159,343   158,911 446,395
Supplemental schedule of major cash flows information:        
Income tax paid (3,013) (437)   (3,259)
Interest paid (145,257) (21,060) (134,180) (73,848)
Supplemental schedule of major non-cash activities:        
Acquisition of investment through effective settlement in other receivables, advance to suppliers and other payables (note 4)       602
Acquisition of property, plant and equipment, construction in progress and other intangible assets through utilization of deposits 257,440 37,325 460,078 704,312
Acquisition of property, plant and equipment, construction in progress and other intangible assets included in accrued expense and other liabilities ¥ 2,181 $ 316 ¥ 99,406 ¥ 50,736